New prognostic systems for multiple myeloma in the context of contemporary therapies Available to Purchase

2.

Palumbo

A

,

Avet-Loiseau

H

,

Oliva

S

, et al.

Revised International Staging System for multiple myeloma: a report from the International Myeloma Working Group

.

J Clin Oncol

.

2015

;

33

(

26

):

2863

-

2869

.

3.

D’Agostino

M

,

Cairns

DA

,

Lahuerta

JJ

, et al.

Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) within the HARMONY project

.

J Clin Oncol

.

2022

;

40

(

29

):

3406

-

3418

.

4.

Tan

JLC

,

Wellard

C

,

Moore

EM

, et al.

The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: real world data results in an Australian and New Zealand population

.

Br J Haematol

.

2023

;

200

(

2

):

e17

-

e21

.

5.

Yan

W

,

Fan

h

,

Xu

J

, et al.

Prognostic value of the second revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma

.

Chin Med J

.

2023

;

136

(

14

):

1744

-

1746

.

6.

Alzahrani

K

,

Pasvolsky

O

,

Wang

Z

, et al.

Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation

.

Br J Haematol

.

2024

;

204

(

5

):

1944

-

1952

.

7.

Kaiser

MF

,

Sonneveld

P

,

Cairns

DA

, et al.

Co-occurrence of cytogenetic abnormalities and high-risk disease in newly diagnosed and relapsed/refractory multiple myeloma

.

J Clin Oncol

.

2025

;

43

(

24

):

2679

-

2691

.

8.

Avet-Loiseau

H

,

Davies

FE

,

Samur

MK

, et al.

International Myeloma Society/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma

.

J Clin Oncol

.

2025

;

43

(

24

):

2739

-

2751

.

9.

Moreau

P

,

Attal

M

,

Garban

F

, et al.

Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials

.

Leukemia

.

2007

;

21

(

9

):

2020

-

2024

.

10.

Hebraud

B

,

Magrangeas

F

,

Cleynen

A

, et al.

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

.

Blood

.

2015

;

125

(

13

):

2095

-

2100

.

11.

Perrot

A

,

Lauwers-Cances

V

,

Tournay

E

, et al.

Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma

.

J Clin Oncol

.

2019

;

37

(

19

):

1657

-

1665

.

12.

Chang

H

,

Qi

X

,

Jiang

A

,

Xu

W

,

Young

T

,

Reece

D

.

1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma

.

Bone Marrow Transpl

.

2010

;

45

(

1

):

117

-

121

.

13.

Schavgoulidze

A

,

Talbot

A

,

Perrot

A

, et al.

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

.

Blood

.

2023

;

141

(

11

):

1308

-

1315

.

14.

Schmidt

TM

,

Fonseca

R

,

Usmani

SZ

.

Chromosome 1q21 abnormalities in multiple myeloma

.

Blood Cancer J

.

2021

;

11

(

4

):

83

-

94

.

15.

Giri

S

,

Huntington

SF

,

Wang

R

, et al.

Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents

.

Blood Adv

.

2020

;

4

(

10

):

2245

-

2253

.

16.

Abdallah

N

,

Greipp

P

,

Kapoor

P

, et al.

Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities

.

Blood Adv

.

2020

;

4

(

15

):

3509

-

3519

.

17.

Fonseca

R

,

Van Wier

SA

,

Chng

WJ

, et al.

Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma

.

Leukemia

.

2006

;

20

(

11

):

2034

-

2040

.

18.

Shah

V

,

Johnson

DC

,

Sherborne

AL

, et al.

Subclonal TP53 copy number is associated with prognosis in multiple myeloma

.

Blood

.

2018

;

132

(

23

):

2465

-

2469

.

19.

Walker

BA

,

Mavrommatis

K

,

Wardell

CP

, et al.

A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis

.

Leukemia

.

2019

;

33

(

1

):

159

-

170

.

20.

Thakurta

A

,

Ortiz

M

,

Blecua

P

, et al.

High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma

.

Blood

.

2019

;

133

(

11

):

1217

-

1221

.

21.

Corre

J

,

Perrot

A

,

Caillot

D

, et al.

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma

.

Blood

.

2021

;

137

(

9

):

1192

-

1195

.

22.

Mithraprabhu

S

,

Hocking

J

,

Ramachandran

M

, et al.

DNA-repair gene mutations are highly prevalent in circulating tumour DNA from multiple myeloma patients

.

Cancers

.

2019

;

11

(

7

):

917

-

931

.

23.

Mina

R

,

Musto

P

,

Rota-Scalabrini

D

, et al.

Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: Pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial

.

Lancet Oncol

.

2023

;

24

(

1

):

64

-

76

.

24.

Lakshman

A

,

Painuly

U

,

Rajkumar

SV

, et al.

Natural history of multiple myeloma with de novo del(17p)

.

Blood Cancer J

.

2019

;

9

(

3

):

32

-

43

.

25.

Rosa-Rosa

JM

,

Cuenca

I

,

Medina

A

, et al.

NGS-based molecular karyotyping of multiple myeloma: Results from the GEM12 clinical trial

.

Cancers

.

2022

;

14

(

20

):

5169

-

5182

.

26.

Abdallah

N

,

Baughn

LB

,

Rajkumar

SV

, et al.

Implications of MYC rearrangements in newly diagnosed multiple myeloma

.

Clin Cancer Res

.

2020

;

26

(

24

):

6581

-

6588

.

27.

Pawlyn

C

,

Cairns

D

,

Kaiser

M

, et al.

The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial

.

Leukemia

.

2020

;

34

(

2

):

604

-

612

.

28.

Mithraprabhu

S

,

Reynolds

J

,

Turner

r

, et al.

Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma

.

Blood Cancer J

.

2023

;

13

(

1

):

25

-

30

.

29.

Song

Y

,

Du

J

,

Jin

X

, et al.

MYC translocation is a valuable marker for the development and relapse of extramedullary disease in multiple myeloma

.

Eur J Haematol

.

2024

;

113

(

6

):

824

-

832

.

30.

Avet-Loiseau

H

,

Fonseca

R

,

Siegel

D

, et al.

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

.

Blood

.

2016

;

128

(

9

):

1174

-

1180

.

31.

Weisel

K

,

Spencer

A

,

Lentzsch

S

, et al.

Daratumumab, bortezomib and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

.

J Hematol Oncol

.

2020

;

13

(

1

):

115

-

126

.

32.

Harrison

S

,

Perrot

A

,

Alegre

A

, et al.

Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics

.

Br J Haematol

.

2021

;

194

(

1

):

120

-

131

.

33.

Kaiser

MF

,

Hall

A

,

Walker

K

, et al.

Daratumumab, cyclophosphamide, bortezomib, lenalidomide and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma

.

J Clin Oncol

.

2023

;

41

(

23

):

3945

-

3955

.

34.

Kuiper

R

,

van Duin

M

,

van Vliet

MH

, et al.

Prediction of high- and low-risk multiple myeloma based on gene expression and the international staging system

.

Blood

.

2015

;

126

(

17

):

1996

-

2004

.

35.

Facon

T

,

Dimopoulos

MA

,

Leleu

XP

, et al.

Isatuximab, bortezomib, lenalidomide and dexamethasone for multiple myeloma

.

N Engl J Med

.

2024

;

391

(

17

):

1597

-

1609

.

36.

Usmani

SZ

,

Facon

T

,

Hungria

V

, et al.

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

.

Nat Med

.

2025

;

31

(

4

):

1195

-

1202

.